» Articles » PMID: 32082486

Sphingomyelin Phosphodiesterase 3 Methylation and Silencing in Oral Squamous Cell Carcinoma Results in Increased Migration and Invasion and Altered Stress Response

Overview
Journal Oncotarget
Specialty Oncology
Date 2020 Feb 22
PMID 32082486
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Neutral sphingomyelinase 2 (nSMase2), the product of the sphingomyelin phosphodiesterase 3 () gene, catalyzes the hydrolysis of sphingomyelin to ceramide. Ceramide acts on various signaling pathways to influence cell proliferation, survival, and stress response. Altered levels of sphingolipids and ceramides have been reported in various cancer types, including oral squamous cell carcinoma (OSCC). OSCC patients exhibit a poor 5-year survival rate of 50%, a figure that has remained stagnant for decades. To overcome this requires a better understanding of the molecular events driving this disease. The molecular analysis of the oral cavity reported here has identified the promoter region as a site of frequent hypermethylation and downregulation in pre-malignant and malignant tissues as compared with healthy control tissues. While lentivirus-induced overexpression of in cell models of oral dysplasia and OSCC did not significantly alter proliferation, it did decrease migration and invasion and increased resistance to the epidermal growth factor receptor (EGFR) inhibitor erlotinib. These results suggest that downregulation is a common event in OSCC progression and may promote the spread of tumor cells.

Citing Articles

Engineered Lipidic Nanomaterials Inspired by Sphingomyelin Metabolism for Cancer Therapy.

Zhu H, Chen H, Wen H, Wang Z, Liu S Molecules. 2023; 28(14).

PMID: 37513239 PMC: 10383197. DOI: 10.3390/molecules28145366.


Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment.

Janneh A, Ogretmen B Cancers (Basel). 2022; 14(9).

PMID: 35565311 PMC: 9104917. DOI: 10.3390/cancers14092183.


Cell surface sphingomyelin: key role in cancer initiation, progression, and immune evasion.

Tallima H, Azzazy H, El Ridi R Lipids Health Dis. 2021; 20(1):150.

PMID: 34717628 PMC: 8557557. DOI: 10.1186/s12944-021-01581-y.


Sphingolipid Pathway as a Source of Vulnerability in IDH1 Glioma.

Dowdy T, Zhang L, Celiku O, Movva S, Lita A, Ruiz-Rodado V Cancers (Basel). 2020; 12(10).

PMID: 33050528 PMC: 7601159. DOI: 10.3390/cancers12102910.

References
1.
Qin J, Kilkus J, Dawson G . The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity. Biochim Biophys Acta. 2015; 1861(2):78-90. PMC: 4691382. DOI: 10.1016/j.bbalip.2015.11.001. View

2.
Tani M, Hannun Y . Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular localization. J Biol Chem. 2007; 282(13):10047-10056. DOI: 10.1074/jbc.M611249200. View

3.
Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

4.
Han J, Molberg K, Sarode V . Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J. 2011; 17(3):223-9. DOI: 10.1111/j.1524-4741.2011.01069.x. View

5.
Wang J, Li J, Gu J, Yu J, Guo S, Zhu Y . Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma. Oncol Lett. 2016; 10(5):3073-3080. PMC: 4665406. DOI: 10.3892/ol.2015.3707. View